Literature DB >> 10486188

Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis.

M M Reinholz1, C M Merkle, J F Poduslo.   

Abstract

Dominant mutations in the copper/zinc superoxide dismutase (SOD1) gene have been observed in 15-20% of familial amyotrophic lateral sclerosis (FALS) cases. The mechanism by which SOD1 mutations result in motor neuron degeneration in FALS mice partly involves oxidative damage and an increased peroxidase activity of the mutant SOD1. A new therapeutic approach designed to eliminate the substrate of this peroxidase activity was examined in two lines of transgenic mice expressing the FALS-linked mutation glycine to alanine (G93A). We investigated the ability of putrescine-modified catalase (PUT-CAT), an antioxidant enzyme that removes hydrogen peroxide and has increased permeability at the blood-brain barrier, to modify the time course of the SOD1 mutation-induced motor neuron disease in these FALS mice. Continuous, subcutaneous administration of PUT-CAT significantly delayed the age at which onset of clinical disease occurred (indicated by loss of splay and/or tremors of hindlimbs) in a high-expressor line of FALS transgenic mice. Intraperitoneal injection of PUT-CAT given two times per week also significantly delayed the onset of clinical disease in a low-expressor line of FALS mice. PUT-CAT also significantly delayed the age at which clinical weakness developed (quantified by measuring the shortening of stride length) in both lines of FALS animals. No significant changes were observed in the survival times of the high-expressor FALS mice in any of the treatment groups. However, a trend toward a prolongation of survival was observed in the PUT-CAT-treated low-expressor FALS mice. These results support the role of free radical-mediated damage in the cascade of events leading to motor neurodegeneration in FALS and indicate that PUT-CAT interacts with a critical step in this cascade to delay the onset of clinical disease as well as the development of clinical weakness in FALS transgenic mice. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486188     DOI: 10.1006/exnr.1999.7142

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  16 in total

1.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

2.  Pericytes Extend Survival of ALS SOD1 Mice and Induce the Expression of Antioxidant Enzymes in the Murine Model and in IPSCs Derived Neuronal Cells from an ALS Patient.

Authors:  Giuliana Castello Coatti; Miriam Frangini; Marcos C Valadares; Juliana Plat Gomes; Natalia O Lima; Natale Cavaçana; Amanda F Assoni; Mayra V Pelatti; Alexander Birbrair; Antonio Carlos Pedroso de Lima; Julio M Singer; Francisco Marcelo M Rocha; Giovani Loiola Da Silva; Mario Sergio Mantovani; Lucia Inês Macedo-Souza; Merari F R Ferrari; Mayana Zatz
Journal:  Stem Cell Rev Rep       Date:  2017-10       Impact factor: 5.739

3.  UCP2 overexpression worsens mitochondrial dysfunction and accelerates disease progression in a mouse model of amyotrophic lateral sclerosis.

Authors:  Pablo M Peixoto; Hyun-Jeong Kim; Brittany Sider; Anatoly Starkov; Tamas L Horvath; Giovanni Manfredi
Journal:  Mol Cell Neurosci       Date:  2013-10-17       Impact factor: 4.314

Review 4.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  Prospects for redox-based therapy in neurodegenerative diseases.

Authors:  A L Friedlich; M F Beal
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

6.  Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis.

Authors:  Bradley J Turner; Julie D Atkin; Manal A Farg; Da Wei Zang; Alan Rembach; Elizabeth C Lopes; Justin D Patch; Andrew F Hill; Surindar S Cheema
Journal:  J Neurosci       Date:  2005-01-05       Impact factor: 6.167

Review 7.  Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:  Michel Dib
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  MR microimaging of amyloid plaques in Alzheimer's disease transgenic mice.

Authors:  Thomas M Wengenack; Clifford R Jack; Michael Garwood; Joseph F Poduslo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

Review 9.  CNS delivery via adsorptive transcytosis.

Authors:  Françoise Hervé; Nicolae Ghinea; Jean-Michel Scherrmann
Journal:  AAPS J       Date:  2008-08-26       Impact factor: 4.009

10.  Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS).

Authors:  Richard J Mead; Ellen J Bennett; Aneurin J Kennerley; Paul Sharp; Claire Sunyach; Paul Kasher; Jason Berwick; Brigitte Pettmann; Guiseppe Battaglia; Mimoun Azzouz; Andrew Grierson; Pamela J Shaw
Journal:  PLoS One       Date:  2011-08-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.